| Gang K Zhang, MD | |
|
3900 Park Nicollet Blvd, St Louis Park, MN 55416-2503 | |
| (952) 993-3180 | |
| Not Available |
| Full Name | Gang K Zhang |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 50 Years |
| Location | 3900 Park Nicollet Blvd, St Louis Park, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447238373 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 30338 (Minnesota) | Secondary |
| 208800000X | Urology | MD61394213 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Carle Foundation Hospital | Urbana, IL | Hospital |
| Olmsted Medical Center | Rochester, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Olmsted Medical Center | 8527970060 | 273 |
| Carle Health Care Incorporated | 3577515774 | 808 |
News Archive
Water fluoridation prevents dental cavities, which are a costly public health concern. But despite the benefits supplemental water fluoridation remains a controversial subject.
A novel device that makes it possible to draw and write using just eye movements has been developed by a CNRS researcher at the Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CNRS/UPMC/Inserm).
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.
Genetic variations in an individual's ability to repair DNA damage may help predict survival in lung cancer patients treated with the common chemotherapy drugs cisplatin or carboplatin, a new study shows.
› Verified 9 days ago
| Entity Name | Park Nicollet Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780621904 PECOS PAC ID: 7911819438 Enrollment ID: O20031104000046 |
News Archive
Water fluoridation prevents dental cavities, which are a costly public health concern. But despite the benefits supplemental water fluoridation remains a controversial subject.
A novel device that makes it possible to draw and write using just eye movements has been developed by a CNRS researcher at the Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CNRS/UPMC/Inserm).
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.
Genetic variations in an individual's ability to repair DNA damage may help predict survival in lung cancer patients treated with the common chemotherapy drugs cisplatin or carboplatin, a new study shows.
› Verified 9 days ago
| Entity Name | Group Health Plan Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710924683 PECOS PAC ID: 1759293954 Enrollment ID: O20031105000417 |
News Archive
Water fluoridation prevents dental cavities, which are a costly public health concern. But despite the benefits supplemental water fluoridation remains a controversial subject.
A novel device that makes it possible to draw and write using just eye movements has been developed by a CNRS researcher at the Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CNRS/UPMC/Inserm).
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.
Genetic variations in an individual's ability to repair DNA damage may help predict survival in lung cancer patients treated with the common chemotherapy drugs cisplatin or carboplatin, a new study shows.
› Verified 9 days ago
| Entity Name | Fairview Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013994359 PECOS PAC ID: 1951213057 Enrollment ID: O20031105000461 |
News Archive
Water fluoridation prevents dental cavities, which are a costly public health concern. But despite the benefits supplemental water fluoridation remains a controversial subject.
A novel device that makes it possible to draw and write using just eye movements has been developed by a CNRS researcher at the Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CNRS/UPMC/Inserm).
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.
Genetic variations in an individual's ability to repair DNA damage may help predict survival in lung cancer patients treated with the common chemotherapy drugs cisplatin or carboplatin, a new study shows.
› Verified 9 days ago
| Entity Name | Olmsted Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952356297 PECOS PAC ID: 8527970060 Enrollment ID: O20031119000240 |
News Archive
Water fluoridation prevents dental cavities, which are a costly public health concern. But despite the benefits supplemental water fluoridation remains a controversial subject.
A novel device that makes it possible to draw and write using just eye movements has been developed by a CNRS researcher at the Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CNRS/UPMC/Inserm).
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.
Genetic variations in an individual's ability to repair DNA damage may help predict survival in lung cancer patients treated with the common chemotherapy drugs cisplatin or carboplatin, a new study shows.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gang K Zhang, MD 6465 Wayzata Blvd, Ste 315, Minneapolis, MN 55426-1728 Ph: () - | Gang K Zhang, MD 3900 Park Nicollet Blvd, St Louis Park, MN 55416-2503 Ph: (952) 993-3180 |
News Archive
Water fluoridation prevents dental cavities, which are a costly public health concern. But despite the benefits supplemental water fluoridation remains a controversial subject.
A novel device that makes it possible to draw and write using just eye movements has been developed by a CNRS researcher at the Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CNRS/UPMC/Inserm).
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.
Genetic variations in an individual's ability to repair DNA damage may help predict survival in lung cancer patients treated with the common chemotherapy drugs cisplatin or carboplatin, a new study shows.
› Verified 9 days ago
William C Sharer, Urology Medicare: Not Enrolled in Medicare Practice Location: 3900 Park Nicollet Blvd, Park Nicollet Clinic - Slp, St Louis Park, MN 55416 Phone: 952-993-3017 Fax: 952-993-1751 | |
Dr. Jocelyn Mary Delia Rieder, Urology Medicare: Accepting Medicare Assignments Practice Location: 5400 Excelsior Blvd, St Louis Park, MN 55416 Phone: 952-993-1000 | |
Dr. Sharon M Hepler, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 3900 Park Nicollet Blvd, St Louis Park, MN 55416 Phone: 952-993-3208 | |
Daniel Zapzalka, Urology Medicare: Accepting Medicare Assignments Practice Location: 3900 Park Nicollet Blvd, St Louis Park, MN 55416 Phone: 952-993-3017 | |
Dr. Nathan B Hoffman, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 5400 Excelsior Blvd, St Louis Park, MN 55416 Phone: 952-993-3190 Fax: 952-993-1160 | |
Jacob Ari Carter Albersheim, MD Urology Medicare: Medicare Enrolled Practice Location: 5400 Excelsior Blvd, St Louis Park, MN 55416 Phone: 952-993-3190 |